Healthtech Solutions (OTC: HLTT) is positioning itself to be a leader in the burgeoning precision oncology market — projected to grow at a 9.9% CAGR from 2019 to 2027 and reach an estimated $99.7 billion — as a result of its newest acquisition: Varian Biopharmaceuticals. Varian is a precision oncology company developing novel therapeutics for the treatment of cancer — a proprietary atypical protein kinase C iota (“aPKCi”) inhibitor for the treatment of various tumor types. Its drug candidates, VAR-101 and VAR-102, leverage the company’s expertise. According to HLTT chairman David Rubin, who was quoted by a recent article, “Varian Bio is at the leading edge of cancer treatment, and it is an honor to have them join our portfolio… The fact that they are developing therapies to target difficult-to-treat cancers such as pancreatic cancer demonstrates just how innovative their team is. Precision oncology is an exciting field, and we’re thrilled to be a part of it.”
To view the full article, visit https://nnw.fm/kcfJX
About Healthtech Solutions Inc.
Healthtech Solutions is a reporting public company. The board of directors is focusing the company’s resources on creating a platform to acquire and/or invest in cutting-edge health care technology in the medical device biopharma and pharmaceutical fields. The goal is to bring these solutions to market.
To date, Healthtech Solutions has invested in three areas of medical technology breakthrough:
- MediScan Inc., which is developing a technology that converts 2D images from a portable ultrasound machine into digital 3D images to provide better diagnosis and more accurate internal trauma views. The goal is a commercial system that can provide the data equivalent to an X-ray, MRI or CT scan, without radiation and at a lower cost.
- RevHeart Inc., which is advancing critical research into the treatment of COVID-related heart muscle injury.
- Varian Biopharmaceutical Inc., a precision oncology company, is the first acquisition of Healthtech Oncology Inc.
Healthtech Solutions has a pipeline of additional acquisitions currently under due diligence.
NOTE TO INVESTORS: The latest news and updates relating to HLTT are available in the company’s newsroom at https://nnw.fm/HLTT
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork